Clinical Trial Site
Auckland, New Zealand
NCT Number: NCT04889391
This was an open-label study to evaluate the absorption, distribution, metabolism, and excretion of radioactivity in healthy male participants following a single 150-milligram (mg) oral dose of carbon-14 ([14C])-ACH-014447 ([14C])-danicopan) containing approximately 100 microcuries (µCi) of [14C].
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Auckland, New Zealand
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Liquid-filled capsules.
Other names: ALXN2040, ACH-014447, ACH-4471, ACH4471, 4471
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose
Time frame: Up to 96 hours postdose
Time frame: Up to 96 hours postdose
Time frame: Up to 96 hours postdose
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
Time frame: Up to 96 hours postdose or maximum of 216 hours postdose for extended collection period
[14C]-Danicopan metabolic profiling in plasma, urine, and feces was performed in samples containing sufficient amounts of radioactivity. The percent of dose represented by each of the metabolites was calculated using the radioactivity concentration equivalent data combined with the metabolic profiling data. The percentage of each identified metabolite to total radioactivity in plasma was estimated based on plasma metabolic profiling data.
Time frame: Day 1 through Day 10
Alexion Pharmaceuticals, Inc.
Industry
A Phase I, Open-Label, Single Dose ADME Study of 14C-ACH-0144471 in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details